GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Aims: The purpose of this study is to compare the effects of two different treatment in patients with endometrial cancer that has not spread outside of the abdomen. This study also aims to determine if radiation therapy combined with chemotherapy is more effective than chemotherapy alone. Another purpose of this study is to collect tissue and blood samples from patients with advanced endometrial cancer to see if special tests can be used to determine which patients may respond to treatment, or have a better prognosis, and which patients may have side effects. Patients will receive either chemotherapy and radiation for 4 cycles, or chemotherapy alone for 6 cycles.
Diagnosis: Advanced Endometrial Carcinoma
Principal Investigator: Jean Hurteau,MD
IRB Approval Number: EH09-534
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698 
Open to Enrollment: Yes 

GOG 0274: The OUTBACK Trial: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival. 
Diagnosis: Advanced Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0273: Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Aims: The major goal of this study is to see if physicans can predict how women will tolerate and complete chemotherapy as prescribed using simple assessments looking at your ability to do activities of daily living. Another goal of the study is to look at how chemotherapy works in older women with cancer, and for this reason you will be asked to allow some research blood to be drawn in order to measure the amount of chemotherapy drug(s) in your blood. You will be asked questions before your first chemotherapy and after the second and fourth cycles to see how you are doing overall. The study doctors will be reviewing this patient-reported information in relation to patients' clinical treatment progress.
Diagnosis: Peritoneal or Fallopian Tube Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-186
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

Randomized Controlled Pilot Trial of Vitamin D3 Replacement or Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
Aims: Ovarian cancer is the leading cause of death among women with gynecologic cancer. Women with a genetic mutation and a family history of breast and ovarian cancer are at high risk of developing ovarian, fallopian, and primary peritoneal cancer. Novel treatments other than surgery which can decrease the risk of developing ovarian, fallopian tube, and primary peritoneal cancer are important. Some research studies have shown that Vitamin D may reduce the risk of some cancers, including ovarian cancer. This study will examine if high dose Vitamin D is tolerable, and see what effects it may have on cells in the ovary related to the biology of cancer, including how cell growth and cell death is regulated. Information gained from this study may help direct future research studies.
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-222
Sponsor: Northwestern University Department of Obstetrics and Gynecology
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC #613327) plus Docetaxel (NSC #628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Aims: In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur).
Diagnosis: Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-299
Sponsor: Gynecologic Oncology Group (GOG)  
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

 

× Alternate Text